Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

NCT02316340 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Vorinostat
DRUG: Hydroxychloroquine
DRUG: Regorafenib

Sponsor

The University of Texas Health Science Center at San Antonio